Alcon announced the US launch of the CyPass Micro-Stent at the annual meeting of the American Academy of Ophthalmology in Chicago. The CyPass Micro-Stent was approved by the FDA in July for use in conjunction with cataract surgery to lower IOP in adult patients with mild to moderate primary open-angle glaucoma.
The CyPass System consists of the CyPass Micro-Stent, contained within a loading device, and a stent delivery tool. The device is designed for placement in the angle of the eye, with the proximal end extending into the anterior chamber, and the distal end residing in the supraciliary space. This allows outflow of fluid from the anterior chamber through the distal end into the supraciliary and suprachoroidal spaces.
In February, Alcon entered into an agreement to acquire Transcend Medical, giving it the rights to the CyPass Micro-Stent system.
“We are excited to launch the CyPass Micro-Stent device in a new segment of glaucoma treatment called minimally-invasive glaucoma surgery, or MIGS,” Sergio Duplan, Region President, North America, Alcon, said in a company news release. “This new treatment option for cataract patients with mild to moderate primary open-angle glaucoma has been demonstrated to have a lasting, significant IOP-lowering effect.”
The CyPass Micro-Stent device is implanted during cataract surgery, just below the surface of the eye, into the supraciliary space. It is designed to lower IOP by enhancing aqueous outflow through one of the natural drainage pathways of the eye, with minimal tissue disruption, which allows the excess fluid in the eye to drain.
Two-year data from the landmark COMPASS study was published recently in the online edition of the peer-reviewed journal Ophthalmology. The data published in Ophthalmology is a follow-up for over 500 mild-to-moderate glaucoma patients who underwent cataract surgery. The randomized clinical study demonstrated safe and sustained 2-year reduction in intraocular pressure and glaucoma medication use after micro-interventional surgical treatment for mild-to-moderate primary open-angle glaucoma.
“Findings from the COMPASS and CYCLE studies are significant and further demonstrate Alcon’s dedication to bringing to market some of the most innovative surgical technologies to effectively treat diseases like glaucoma,” Franck Leveiller, Head of Global Research & Development, Alcon, said in the news release. “We are proud to be working with glaucoma experts and surgeons in the US and around the world to bring this new treatment option to as many eligible patients as possible.”